Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases. Its lead compound, Aramchol™, is currently in Phase III trials for the treatment of non-alcoholic steato-hepatitis (NASH) and fibrosis.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.